Impax Laboratories has signed definitive agreements with Teva Pharmaceutical and affiliates of Allergan for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms for $586 million. The deal also includes the return to Impax of its rights to its pending abbreviated new drug application (ANDA) for the generic equivalent to Concerta (methylphenidate hydrochloride). Impax is expected to add a portfolio of 15 currently marketed ge...